The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Prevalence of human leukocyte antigen-B27 supertype in the context of positively charged neoepitopes and association with PD-L1 as an immune escape mechanism.
 
Charlene Marie Fares
No Relationships to Disclose
 
Amy Lauren Cummings
No Relationships to Disclose
 
Matthew Karl Theisen
No Relationships to Disclose
 
Jaklin Gukasyan
No Relationships to Disclose
 
Jackson P Lind-Lebuffe
No Relationships to Disclose
 
Wisdom O Akingbemi
No Relationships to Disclose
 
Debory Y Li
No Relationships to Disclose
 
Paige M Brodrick
No Relationships to Disclose
 
Nawal M Yessuf
No Relationships to Disclose
 
Chantal Ava Barksdale
No Relationships to Disclose
 
Deborah J.L. Wong
Consulting or Advisory Role - Bristol-Myers Squibb; Genentech/Roche; Sanofi/Aventis
Research Funding - ARMO BioSciences (Inst); Astellas Pharma (Inst); AstraZeneca/MedImmune (Inst); BioMed Valley Discoveries (Inst); Bristol-Myers Squibb (Inst); Enzychem Lifesciences (Inst); FSC Pediatrics (Inst); Genentech/Roche (Inst); Kura Oncology (Inst); Lilly; Merck Serono (Inst); Merck Sharp & Dohme (Inst); Pfizer (Inst); Regeneron (Inst)
 
Aaron Elliott Lisberg
Employment - Boston Scientific (I)
Stock and Other Ownership Interests - Boston Scientific (I)
Consulting or Advisory Role - AstraZeneca; Bristol-Myers Squibb; Jazz Pharmaceuticals; Leica Biosystems; Novocure; Pfizer
Research Funding - AstraZeneca; Calithera Biosciences; Daiichi Sankyo; Dracen
 
Edward B. Garon
Consulting or Advisory Role - Dracen; EMD Serono; GlaxoSmithKline; Novartis
Research Funding - AstraZeneca (Inst); Bristol-Myers Squibb (Inst); Dynavax Technologies (Inst); EMD Serono (Inst); Genentech (Inst); Iovance Biotherapeutics (Inst); Lilly (Inst); Merck (Inst); Mirati Therapeutics (Inst); Neon Therapeutics (Inst); Novartis (Inst)